Debio 0719 - Debiopharm

Home » Media » Publications

Debio 0719

Date	Article Title
23 Feb 2009	Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist
15 Aug 2008	Cross-talk between LPA1 and Epidermal Growth Factor Receptors Mediates Up-regulation of Sphingosine Kinase 1 to Promote Gastric Cancer Cell Motility and Invasion
20 Jun 2006	The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases
23 Apr 2004	Lysophosphatidic Acid and Autotaxin Stimulate Cell Motility of Neoplastic and non-neoplastic cells through LPA
20 Feb 2004	Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA
16 Jul 2003	Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group